Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.62 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.39 |
| ▸ | TTK | P33981 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240349 | 0.90 | AURKA (0.63) | AURKAAURKBPTK6TTKCHEK1 | |
| SCHEMBL8241212 | 0.88 | AURKA (0.61) | AURKAAURKBPTK6TTKCHEK1 | |
| SCHEMBL8246048 | 0.82 | AURKA (0.66) | AURKAAURKBPTK6TTKCHEK1 | |
| SCHEMBL8247167 | 0.81 | AURKA (0.69) | AURKAAURKBPTK6TTKMAPKAPK5 | |
| SCHEMBL8247273 | 0.81 | AURKA (0.69) | AURKAAURKBTTKCHEK1MAPKAPK5 | |
| SCHEMBL14530382 | 0.80 | AURKA (0.71) | AURKAAURKBPTK6TTKMAPKAPK5 | |
| SCHEMBL8240843 | 0.80 | AURKA (0.64) | AURKAAURKBPTK6TTKMAPKAPK5 | |
| SCHEMBL8246792 | 0.80 | AURKA (0.62) | AURKAAURKBPTK6TTKMAPKAPK5 | |
| SCHEMBL8240292 | 0.79 | AURKA (0.70) | AURKAAURKBPTK6TTKMAPKAPK5 | |
| SCHEMBL12404395 | 0.79 | AURKA (0.63) | AURKAAURKBPTK6TTKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058873-A2 | IMIDAZOPYRAZINES AS CYCLIN DEPENTEND KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CHEK1, CDC25A | AURKA 40/4885AURKB 27/4885PTK6 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.